Business Context and Reporting Period
This Form 8-K Current Report, dated December 12, 2024, concerns GoodRx Holdings, Inc. (GDRX). The filing primarily addresses Item 5.02 regarding the appointment of a new Chief Executive Officer and President.
Key Financial Metrics
The filing does not report operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the executive compensation package for the newly appointed CEO, Wendy Barnes:
- Base Salary: $825,000 annually.
- Target Bonus: 100% of base salary ($825,000).
- Signing Bonus: $550,000 one-time cash payment.
- Equity Grants:
- Initial Restricted Stock Unit (RSU) Award: $9,000,000 aggregate value.
- Initial Stock Option: $9,000,000 aggregate value.
- Additional RSU Award: $2,000,000 aggregate value.
- Severance: 12 months of base salary (18 months in Change in Control scenarios) plus pro-rated bonus and accelerated vesting of the Additional RSU Award.
Material Changes
The primary material change is the leadership transition at the executive level:
- Appointment: Wendy Barnes was appointed Chief Executive Officer and President, effective January 1, 2025.
- Succession: Ms. Barnes succeeds Scott Wagner, who served as Interim Chief Executive Officer.
- Board Election: Ms. Barnes was elected as a Class I director, with a term expiring at the 2027 Annual Meeting of Stockholders.
Outlook, Risks, and Management Commentary
Management Commentary: The Board believes Ms. Barnes is qualified due to her significant leadership experience in the healthcare industry, including her tenure as CEO of RxBenefits, Inc. (since May 2022) and various roles at Express Scripts Holding Company (2013–2022).
Contingencies and Risks:
- Clawback Provision: If Ms. Barnes' employment is terminated prior to the first anniversary (excluding death, disability, termination without cause, or good reason), she must repay the unearned portion of the Signing Bonus on a pro-rata basis.
- Termination Payment: If employment does not commence on the Effective Date due to termination by GoodRx other than for "cause," the company will pay $1,650,000 in a lump sum.
- Equity Vesting: Equity awards are subject to continued employment through specific vesting dates, with the Initial RSU and Option vesting 25% on January 15, 2026, and quarterly thereafter.
Investor Verification Checklist
- Verify the commencement date of Wendy Barnes' employment (expected January 1, 2025).
- Confirm the final grant date and share count for the equity awards, which depend on the closing share price over the last 20 trading days preceding the grant.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause," "good reason," and "disability."
- Monitor the transition plan from Interim CEO Scott Wagner to ensure operational continuity.